Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 2/20 | 0.41 |
| ▸ | TUBB | P07437 | 2/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.41 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.41 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20591983 | 1.00 | TUBB4A (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29354525 | 0.95 | TUBB4A (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1277493 | 0.95 | TUBB4A (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29803806 | 0.92 | TUBB4A (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29602867 | 0.88 | ASAH1 (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL20897341 | 0.88 | ASAH1 (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6372854 | 0.82 | TUBB4A (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6896839 | 0.80 | ASAH1 (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL21073734 | 0.80 | DGAT1 (0.51) | — | |
| SCHEMBL21176002 | 0.79 | TUBB4A (0.40) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119562958-A | Methods for preparing NAG-25 carbohydrate targeting moieties and intermediates thereof | 安进公司 | 2025-03-04 | — | — | CN | claimed |
| US-20240122912-A1 | A NANOFORMULATION FOR GLIOMA TREATMENT AND PROCESS FOR ITS PREPARATION THEREOF | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2024-04-18 | — | — | US | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260035430-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA AS (DK) | 2026-02-05 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-12473339-B2 | Acylated glucagon analogues | ZEALAND PHARMA A/S (DK) | 2025-11-18 | — | — | US | disclosed |
| EP-4272751-B1 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | ZP SPV 3 K/S (DK) | 2025-09-24 | — | — | EP | disclosed |
| CN-112236428-B | Antiproliferative compounds and uses thereof | 默克专利股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20250051390-A1 | NOVEL ADIPONECTIN-DERIVED PEPTOID DERIVATIVE AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2025-02-13 | — | — | US | disclosed |
| US-20250049891-A1 | NOVEL PEPTIDE DERIVATIVE DERIVED FROM ADIPONECTIN AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2025-02-13 | — | — | US | disclosed |
| EP-3337795-B1 | PIPERIDINOBENZODIAZEPINE COMPOUNDS WITH ANTI PROLIFERATIVE ACTIVITY | FEMTOGENIX LTD (GB) | 2022-06-22 | — | — | EP | disclosed |
| EP-4010314-A1 | HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3985016-A1 | GIP AGONIST COMPOUNDS AND METHODS | Zealand Pharma A/S (DK) | 2022-04-20 | — | — | EP | disclosed |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-11274136-B2 | Acylated glucagon analogue | ZEALAND PHARMA A/S (DK) | 2022-03-15 | — | — | US | disclosed |
| US-20220073583-A1 | ACYLATED GLUCAGON ANALOGUES | ZEALAND PHARMA A/S (DK) | 2022-03-10 | — | — | US | disclosed |
| WO-2022040473-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220041676-A1 | GIP AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2022-02-10 | — | — | US | disclosed |
| US-11235316-B2 | Catalysts for chemical reactions in a water-surfactant mixture | NOVARTIS AG (CH) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | TUBB4A 1106/4885TUBB 474/4885TUBA3C 830/4885 |
| US-11235316-B2 | Catalysts for chemical reactions in a water-surfactant mixture | LSS, DCXR, CEL | TUBB4A 2617/4885TUBB 2425/4885TUBA3C 1857/4885 |
| US-20250049891-A1 | NOVEL PEPTIDE DERIVATIVE DERIVED FROM ADIPONECTIN AND USE THEREOF | ADIPOR1, ADIPOR2, PRKAG1 | TUBB4A 4356/4885TUBB 4143/4885TUBA3C 4671/4885 |
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | CNR1, MTNR1B, MTNR1A | TUBB4A 1670/4885TUBB 1133/4885TUBA3C 1395/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | TUBB4A 1511/4885TUBB 890/4885TUBA3C 1821/4885 |
| US-20250051390-A1 | NOVEL ADIPONECTIN-DERIVED PEPTOID DERIVATIVE AND USE THEREOF | ADIPOR1, ADIPOR2, PRKAG1 | TUBB4A 3917/4885TUBB 3762/4885TUBA3C 4565/4885 |
| US-20220041676-A1 | GIP AGONIST COMPOUNDS AND METHODS | GIPR, GLP1R, GPR119 | TUBB4A 4525/4885TUBB 4610/4885TUBA3C 4594/4885 |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | TUBB4A 3083/4885TUBB 1593/4885TUBA3C 1615/4885 |
| US-11274136-B2 | Acylated glucagon analogue | GLP1R, GCGR, GIPR | TUBB4A 4193/4885TUBB 4307/4885TUBA3C 3999/4885 |
| US-20220073583-A1 | ACYLATED GLUCAGON ANALOGUES | GLP1R, GCGR, GIPR | TUBB4A 4201/4885TUBB 4261/4885TUBA3C 3894/4885 |
| US-20260035430-A1 | ACYLATED GLUCAGON ANALOGUES | GLP1R, GCG, GCGR | TUBB4A 4573/4885TUBB 4563/4885TUBA3C 4665/4885 |
| US-12473339-B2 | Acylated glucagon analogues | GLP1R, GCGR, GIPR | TUBB4A 4201/4885TUBB 4261/4885TUBA3C 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.